Market Overview

Teva Says Omacetaxine Mepesuccinate Shows Activity in CML

Share:
Related TEVA
Have You Heard About This Generic EpiPen Maker?
10 Notable Stocks Trading Ex-Dividend Thursday, August 18
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2016 Update (Seeking Alpha)

Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.

Posted-In: News FDA

 

Related Articles (TEVA)

View Comments and Join the Discussion!